JP5779799B2 - ２’−フルオロ−６’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法 - Google Patents

２’−フルオロ−６’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法 Download PDF

Info

Publication number
JP5779799B2
JP5779799B2 JP2012539968A JP2012539968A JP5779799B2 JP 5779799 B2 JP5779799 B2 JP 5779799B2 JP 2012539968 A JP2012539968 A JP 2012539968A JP 2012539968 A JP2012539968 A JP 2012539968A JP 5779799 B2 JP5779799 B2 JP 5779799B2
Authority
JP
Japan
Prior art keywords
compound
hbv
virus
hepatitis
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012539968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510904A5 (https=
JP2013510904A (ja
Inventor
チュン， ケー． チュ，
チュン， ケー． チュ，
ジャーニン ウォン，
ジャーニン ウォン，
Original Assignee
ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド
ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド, ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド filed Critical ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド
Publication of JP2013510904A publication Critical patent/JP2013510904A/ja
Publication of JP2013510904A5 publication Critical patent/JP2013510904A5/ja
Application granted granted Critical
Publication of JP5779799B2 publication Critical patent/JP5779799B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012539968A 2009-11-16 2010-11-16 ２’−フルオロ−６’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法 Expired - Fee Related JP5779799B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28134209P 2009-11-16 2009-11-16
US61/281,342 2009-11-16
PCT/US2010/056808 WO2011060408A2 (en) 2009-11-16 2010-11-16 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections

Publications (3)

Publication Number Publication Date
JP2013510904A JP2013510904A (ja) 2013-03-28
JP2013510904A5 JP2013510904A5 (https=) 2014-01-09
JP5779799B2 true JP5779799B2 (ja) 2015-09-16

Family

ID=43992463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539968A Expired - Fee Related JP5779799B2 (ja) 2009-11-16 2010-11-16 ２’−フルオロ−６’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法

Country Status (14)

Country Link
US (1) US8946244B2 (https=)
EP (1) EP2501709A4 (https=)
JP (1) JP5779799B2 (https=)
KR (2) KR101961601B1 (https=)
CN (1) CN102725302B (https=)
AP (1) AP2012006310A0 (https=)
AU (1) AU2010319999B2 (https=)
CA (1) CA2781054A1 (https=)
EA (1) EA201270632A1 (https=)
IL (1) IL219748A0 (https=)
MX (1) MX2012005601A (https=)
PH (1) PH12012500963B1 (https=)
WO (1) WO2011060408A2 (https=)
ZA (1) ZA201204356B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
US8816074B2 (en) * 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CN102850402B (zh) * 2011-06-28 2016-08-03 李勤耕 非环核苷环状磷酸酯类衍生物，其制备方法及医药用途
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
CN102603652A (zh) * 2011-12-27 2012-07-25 河南师范大学 5-甲酰基嘧啶碳环核苷及制备方法
US8673926B2 (en) * 2012-02-14 2014-03-18 University Of Georgia Research Foundation, Inc. Spiro[2.4]heptanes for treatment of flaviviridae infections
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
CN103804417B (zh) * 2012-11-13 2017-09-19 北京美倍他药物研究有限公司 抗乙肝病毒药物
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
JP2016507569A (ja) * 2013-02-07 2016-03-10 トビラ セラピューティクス， インコーポレイテッド ラミブジン結晶塩
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015013352A2 (en) * 2013-07-25 2015-01-29 Patel Hasmukh B Nucleoside phosphoramidates and phosphoramidites
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US9334273B1 (en) 2014-03-05 2016-05-10 University Of Georgia Research Foundation, Inc. Efficient and stereoselective synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA)
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CN106466300B (zh) * 2015-08-12 2019-06-21 复旦大学 一种装载难溶性药物的复合壳聚糖纳米粒制剂及其制备方法和应用
WO2017127461A1 (en) * 2016-01-18 2017-07-27 Sensor Electronic Technology, Inc. Semiconductor device with improved light propagation
JP6857365B2 (ja) 2016-03-11 2021-04-14 国立大学法人 鹿児島大学 抗肝腫瘍ウイルス剤
WO2017176392A1 (en) 2016-04-07 2017-10-12 University Of Georgia Research Foundation, Inc. Synthesis of 2'-fluoro-6'-methylene-carbocyclic adenosine (fmca) and 2'-fluoro-6'-methylene-carbocyclic guanosine (fmcg)
JP6894923B2 (ja) 2016-04-11 2021-06-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞性及び線維性の疾患の処置方法
US10653678B2 (en) 2016-04-11 2020-05-19 Genfit Methods of treatment for cholestatic and fibrotic diseases
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
WO2018092728A1 (ja) * 2016-11-16 2018-05-24 国立研究開発法人国立国際医療研究センター 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体
WO2018133835A1 (en) * 2017-01-20 2018-07-26 National Institute Of Biological Sciences, Beijing Nucleoside analogue regulating mammalian circadian rhythm
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
JP7496132B2 (ja) * 2018-08-31 2024-06-06 国立大学法人 鹿児島大学 核酸アナログ及び抗ｂ型肝炎ウイルス剤
CN109846887B (zh) * 2019-03-22 2022-12-09 南京大学 2-氨基嘌呤-6（h）硫酮在制备单纯疱疹病毒的抑制剂中的应用
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
WO2025207435A1 (en) * 2024-03-25 2025-10-02 University Of Georgia Research Foundation, Inc. 2'-fluoro-6'-methylene carbocyclic nucleos(t)ides as potent antiviral agents for the treatment of wild-type and mutant hepatitis b virus (hbv) infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396623A (en) 1981-08-26 1983-08-02 Southern Research Institute Carbocyclic analogs of uracil nucleosides as antiviral agents
GB8520553D0 (en) * 1985-08-16 1985-09-25 Glaxo Group Ltd Chemical compound
PT2415776T (pt) * 1998-08-10 2016-07-07 Novartis Ag Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
CA2405502A1 (en) * 2000-03-29 2001-10-04 Georgetown University Method of treating hepatitis delta viral infection
US6841718B2 (en) 2000-05-10 2005-01-11 Cerno Biosciences Llc Transgenic plants incorporating traits of Zostera marina
SK286630B6 (sk) * 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US8816074B2 (en) * 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections

Also Published As

Publication number Publication date
ZA201204356B (en) 2013-02-27
AP2012006310A0 (en) 2012-06-30
CN102725302B (zh) 2016-04-06
CA2781054A1 (en) 2011-05-19
KR101961601B1 (ko) 2019-03-25
KR101840479B1 (ko) 2018-03-20
KR20180014179A (ko) 2018-02-07
EP2501709A4 (en) 2013-11-13
EA201270632A1 (ru) 2013-01-30
IL219748A0 (en) 2012-07-31
PH12012500963A1 (en) 2018-05-15
EP2501709A2 (en) 2012-09-26
US8946244B2 (en) 2015-02-03
US20130005677A1 (en) 2013-01-03
AU2010319999B2 (en) 2014-01-16
WO2011060408A3 (en) 2011-10-13
WO2011060408A2 (en) 2011-05-19
PH12012500963B1 (en) 2018-08-10
AU2010319999A1 (en) 2012-06-21
HK1172628A1 (zh) 2013-04-26
JP2013510904A (ja) 2013-03-28
MX2012005601A (es) 2012-08-01
CN102725302A (zh) 2012-10-10
KR20120092153A (ko) 2012-08-20

Similar Documents

Publication Publication Date Title
JP5779799B2 (ja) ２’−フルオロ−６’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法
KR102002886B1 (ko) 2’-플루오로-6’-메틸렌 탄소환 뉴클레오시드 및 바이러스 감염을 치료하는 방법
US11082386B2 (en) 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
JP2024525160A (ja) Ｐｄ－ｌ１を標的とするための方法及び組成物
KR20230030056A (ko) Pd-l1을 표적화하기 위한 방법 및 조성물
JP2023539463A (ja) Ｐｄ－ｌ１を標的とするための方法及び組成物
CN119212987A (zh) 用于靶向pd-l1的方法和组合物
KR20100041798A (ko) 신규 ｈｉｖ 역전사효소 억제제
US20230295212A1 (en) Compounds and methods for treating disease
WO2024103016A1 (en) 4'-halomethyl-cytidine phosphoramidates and related compounds and their use in treating medical conditions
CN117677620A (zh) 恩替卡韦（etv）的抗病毒前药及其制剂
HK1172628B (en) 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
HK1194385A (en) 2'-fluoro-6'-methylene carbocyclic nuceosides and methods of treating viral infections
HK1194385B (en) 2'-fluoro-6'-methylene carbocyclic nuceosides and methods of treating viral infections
EP4103567B1 (en) Spirocyclic inhibitors of hepatitis b virus
WO2024114709A1 (en) A crystal form of a fused heterocycle derivative compound
WO2024107850A1 (en) Halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds and their use in treating medical conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150622

R150 Certificate of patent or registration of utility model

Ref document number: 5779799

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees